Earnings Releases·Nov 9, 2026, 4:10 PM ET

Myomo — Third Quarter 2026 Earnings Summary

Revenue grew 22% year-over-year to $12.3 million in Q3 2026, while gross margin expanded 750 basis points to 71.3% and operating loss narrowed to $1.7 million from $3.5 million in the prior year period.
The company achieved breakeven Adjusted EBITDA in Q3 2026, with cash burn in operating activities decreasing to $1.3 million, and management projects full-year cash burn to remain under $2 million in the second half of the year.
Full-year 2026 revenue guidance was narrowed to $46–47 million, positioned at the upper end of the previous raised range, driven by a 13% increase in order volume and recurring patient sources rising to 54% of revenue.
Strategic progress includes the addition of 600 patients to the MyoConnect pipeline, new payer contracts covering 35 million lives, and the appointment of a new Chief Commercial Officer to lead commercial expansion.